Core Insights - Chemomab Therapeutics has successfully completed an FDA End-of-Phase 2 meeting, achieving alignment on a clear pathway to potential approval for its treatment of primary sclerosing cholangitis (PSC) based on a single Phase 3 trial [1][3][12] - The Phase 2 SPRING trial results for nebokitug have been recognized as significant, with multiple scientific presentations raising awareness of its potential as a first disease-modifying treatment for PSC and other fibro-inflammatory conditions [1][4][12] - Ongoing discussions with strategic partners are aimed at advancing the necessary activities for the timely initiation of the Phase 3 trial [3][12] Company Developments - The Phase 2 SPRING trial data was published in the American Journal of Gastroenterology, indicating that nebokitug was generally safe and well-tolerated, with improvements in biomarkers for inflammation and fibrosis, particularly at the 20 mg/kg dose [4] - Data from the SPRING trial was featured in three poster presentations at the AASLD The Liver Meeting® 2025, all designated as "posters of distinction," confirming nebokitug's positive safety profile and disease-modifying potential [4] - Chemomab has received FDA and EMA Orphan Drug designations for nebokitug in PSC and systemic sclerosis, highlighting its therapeutic potential in severe fibro-inflammatory diseases [12] Financial Highlights - As of December 31, 2025, Chemomab reported cash, cash equivalents, and short-term bank deposits of $10.4 million, down from $14.3 million in 2024, with a cash runway expected to last until the end of Q1 2027 [10] - Research and Development (R&D) expenses for the fourth quarter were $1.1 million, and $5.8 million for the full year, a decrease from $2.4 million and $11.3 million in 2024, primarily due to the completion of the Phase 2 trial [10] - The net loss for the fourth quarter was $1.9 million, or less than $0.01 per share, and for the full year, it was $9.0 million, or less than $0.02 per share, compared to a net loss of $13.9 million in 2024 [10][17]

Core Insights - The new clinical data confirms the potential of nebokitug (CM-101) as a first-in-class treatment for primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases [2][8] - Comprehensive proteomic analyses indicate that treatment with nebokitug resulted in significant and dose-dependent improvements in various biomarkers related to fibro-inflammatory disease pathways [2][3] - The pharmacokinetic and pharmacodynamic data from the Phase 2 SPRING trial demonstrate effective and dose-dependent antibody-target engagement [4][8] Group 1: Clinical Data and Findings - Nebokitug-treated patients exhibited significant and dose-dependent changes in multiple proteins related to fibrosis, immune cell recruitment, and inflammation [2][3] - The treatment was linked to downregulation of disease-related proteins and pathways involved with leukocyte migration, cytokine activity, chemokine activity, and collagen binding [3] - The analysis provided new insights into PSC disease-related pathways and additional biological evidence of the clinical activity of nebokitug [2] Group 2: Pharmacokinetics and Pharmacodynamics - PK analyses indicated dose-proportional increases in the concentration of nebokitug, with steady-state levels achieved after the fourth dose [4] - Increased levels of nebokitug corresponded with increased levels of its CCL24 target, reflecting effective antibody-target engagement [4] - Linear regression analyses found trends between increasing patient exposure to nebokitug and decreasing levels of relevant PSC disease biomarkers, including liver enzyme and transient elastography scores [4] Group 3: Company Overview and Future Plans - Chemomab Therapeutics is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [8] - The company has reported positive results from four clinical trials of nebokitug and is preparing for a potential Phase 3 trial based on positive data from the Phase 2 SPRING trial [8] - Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC [8]